TCM
CLDI icon

Tradewinds Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Tradewinds Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25 Hold
101
– – ﹤0.01% 700
2025
Q4 		$119 Hold
101
– – ﹤0.01% 650
2025
Q3 		$154 Buy
101
+18
+22% +$76 ﹤0.01% 640
2025
Q2 		$230 Hold
83
– – ﹤0.01% 593
2025
Q1 		$567 Hold
83
– – ﹤0.01% 574
2024
Q4 		$1.15K Buy
+83
New +$1.56K ﹤0.01% 535

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tradewinds Capital Management's CLDI Position: Q1 2026 in Review

Tradewinds Capital Management held its Calidi Biotherapeutics (CLDI) position steady in Q1 2026 at 101 shares worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #700.

Tradewinds Capital Management first reported a position in CLDI in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.15K in Q4 2024. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Tradewinds Capital Management held 101 shares of Calidi Biotherapeutics worth $25 as of Q1 2026.
  • Tradewinds Capital Management left its Calidi Biotherapeutics share count unchanged in Q1 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of Tradewinds Capital Management's portfolio in Q1 2026, its #700 holding.
  • Tradewinds Capital Management first reported a position in Calidi Biotherapeutics in Q4 2024 and has held it in 6 quarters since.
  • Tradewinds Capital Management's Calidi Biotherapeutics position peaked at $1.15K in Q4 2024.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Tradewinds Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.